Anti-DGAT2 antibody
Description
Application Data
Description
-
An antibody against diacylglycerol acyltransferase (DGAT2), it has a role in metabolism.
Application Data
-
Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb2005783 Antibody Anti-DGAT2 antibody Antigen Peptide KLH conjugated synthetic peptide crb1200992 Protein ID UniProtKB - Q96PD7 (Human) Aliases Diacylglycerol O-acyltransferase 2, Acyl-CoA retinol O-fatty-acyltransferase, Diglyceride acyltransferase 2 Cross-Reactivity Human Host Species Rabbit Antibody Type Polyclonal Concentration 2.0 mg/ml Glycine Target Diacylglycerol O-acyltransferase 2 Storage This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/thaw cycles. References Calle et al., (2021). ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials. Nat. Med., 27(10): 1836. doi: 10.1038/s41591-021-01489-1.
Roe et al., (2018). The Role of Diacylglycerol Acyltransferase (DGAT) 1 and 2 in Cardiac Metabolism and Function. Sci Rep, 8(1): 1. doi: 10.1038/s41598-018-23223-7.
Triglyercide synthesis can be catalysed by diacylglycerol acyltransferase DGAT1 or DGAT2. Triglyceride accumulation is a clinical feature of ageing and diabetic patients. The rate of triglyceride turnover seems to be a lipotoxic cardiomyopathy but the importance of DGAT2 in cardia triglyceride metabolism is not clear.
DGAT2 is a key link between carbohydrate-induced hypertriglyceridaemia and hepatic steatosis. Knockdown of Dgat2 protects against fat-induced hepatic insulin resistance. DGAT2 inhibition is a target for the therapeutic treatment of non-alcoholic fatty liver disease (NAFLD) and insulin resistance in type 2 diabetes.